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ABSTRACT 
The objective of the review is to present the contemporary approaches involved in colonic drug targeting for the therapy of inflammatory bowel 
disease (IBD). The adverse reactions and side-effects of the conventional drug delivery systems are largely on account of the systemic absorption of 
the drugs from the small intestine. Moreover, in current drug delivery systems, the drug has to be frequently administered and also in larger doses 
which greatly reduces patient compliance. Various approaches which are being described here mainly target the colonic region specifically for 
improved therapy of IBD, by increasing localization and accessibility of the drug to the target site. Also, these approaches will result in the reduction 
of dose and minimization of adverse effects combined with the use of conventional drug delivery systems. 
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INTRODUCTION 
Inflammatory bowel disease (IBD) involves inflammatory conditions of 
the colon and small intestine due to inappropriate mucosal immune 
activation. Crohn's disease and Ulcerative colitis are the major types of 
IBD. Crohn's disease also called regional enteritis (because of frequent 
ileal involvement) affects the entire gastrointestinal tract. Ulcerative 
colitis affects only the colon and the rectum and extends only into the 
mucosa and submucosa; it occurs only in the innermost layer of the 
lining of the intestine [1]. The etiology of the IBD is still completely 
unidentified which makes its treatment a huge challenge [2]. IBD is a 
result of environmental and genetic factors interactions leading to 
immunological responses and intestinal inflammation. Dietary patterns 
are also a hazardous factor for ulcerative colitis [1]. Evidence suggests 
that the causes for uncontrolled inflammation and inadequate repair and 
destruction of the gut epithelium in Crohn’s disease are because of the 
loss in commensal bacteria tolerance [2]. 
Symptoms of the disease depend on the type of IBD. Abdominal pain in 
the lower left part and diarrhea are been observed in patients with 
ulcerative colitis, which causes weight loss and blood on rectal 
examination. Pain in the lower right abdomen is observed in Crohn’s 
disease, but with less frequent rectal bleeding than in ulcerative colitis. 
Despite Crohn's disease and Ulcerative colitis are different, the following 
symptoms are common in both: abdominal pain, diarrhea, rectal 
bleeding, loss of weight, and severe internal cramps/muscle spasms in 
the pelvic area. Anemia is the most common extraintestinal complication 
of inflammatory bowel disease. Stool inflammatory markers assessment 
followed by colonoscopy with biopsy of pathological lesions is the most 
common way of diagnosis.  
The medical or surgical remedy is not available for IBD. Oral colon 
targeted drug delivery is used for the therapy of IBD, which is largely 
effective only in mitigating symptoms [3, 4]. Both ulcerative colitis and 
Crohn’s disease treatment are similar, although significant differences 
exist including limited or lack of response and increased need for 
surgery in Crohn’s disease [5]. Treatment mainly involves the use of 
medications, like immunosuppressive drugs and anti-inflammatory 
compounds which reduce the symptoms and decrease inflammations of 
the lining. But attaining remission in IBD patients remains a challenge.  
Under certain conditions, when treatment using medications fails, 
the large intestine is removed by a surgery termed colectomy. 
Colectomy can cure ulcerative disease, but unfortunately, Crohn’s 
disease can reappear after surgery. Certain side effects associated 
with most pharmaceutical compounds also will result in reduced 
patient compliance and worsening of the disease. Oral 
administration of anti-inflammatory drugs has been proved effective 
but has certain restrictions upon administering high doses, as the 
administered drug is delivered to nonspecific cells, which results in 
either infusion reactions or unsavory side effects.  
Various international publications of the past few decades are 
summarized from the reputed sources (Elsevier, Pubmed, and NCBI) to 
emphasize the significance of the approaches in colonic drug targeting 
for the treatment of IBD. These approaches are aimed at developing drug 
delivery methods to distribute anti-inflammatory drugs to the areas of 
the most afflicted parts of the gastrointestinal tract [1]. The primary 
approaches for colonic drug delivery involve: (i) drugs linked covalently 
with polymers as a prodrug, (ii) pH-sensitive polymer (Eudragit 
polymers), bioadhesive polymers, or biodegradable polymeric coatings, 
and (iii) microbially triggered delivery of drugs. Further to the above 
approaches, there are novel approaches such as (i) pressure controlled 
delivery, (ii) CODESTM (combined approach of pH-dependent and 
microbially triggered delivery), (iii) osmotic drug delivery, and (iv) 
multiparticulate systems like microspheres and nanoparticles [6]. These 
approaches are developed for the therapy of IBD for increasing drug 
localization and accessibility of drug at the target site, reduction of dose, 
and side-effects associated with the conventional drug delivery systems 
[4, 7-10]. 
 
Table 1: Comparison of conventional drug delivery systems and novel site-specific colon targeted approaches in the treatment of IBD 
Conventional drug delivery systems Novel site-specific colon targeted approaches Reference 
Systemic absorption takes place because of delivery to non-
specific cells 
Systemic absorption is very low due to its site-specific nature [1] 
Side effects are possible due to systemic absorption of drugs Very minimal side effects due to its site-specific nature [1, 4] 
High doses of the drug have to be administered for 
obtaining the desired therapeutic effect 
Reduction of doses is possible. The desired therapeutic effect can be 
obtained with very low doses 
[1] 
Decreased patient compliance due to high frequency and 
dose of drugs administered 
Increased patient compliance due to less frequency and dose of drugs 
administered 
[4, 7-10] 
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Bioadhesive pellets of curcumin and cyclosporine with pH-
sensitive coating 
Bioadhesive pellets are prepared by using Curcumin, Cyclosporine, 
along with methacrylate copolymer (Eudragit® S100), 
Hydroxypropylcellulose (HPC) and Carbomer 940 (CP940) (1:1 
ratio). Curcumin is used for its anti-inflammatory properties along 
with cyclosporine which is an immunomodulatory drug, for its 
synergistic effect. Bioadhesive pellets are prepared by 
extrusion/spheronization method with core material containing 
bioadhesive CP940 and HPC-H. Eudragit® S100 polymer is used to 
coat bioadhesive pellets, to deliver the drugs to the colon. 
Microcrystalline cellulose (Avicel PH101) is founded as the best 
core-forming agent. In vitro dissolution studies of coated pellets 
shown that 12.327±0.342 % of Curcumin and 14.751±0.112 % of 
Cyclosporine are released in pH 6.8 at the end of 6 h and in pH 7.4 at 
the end of 24 h 71.278±0.100 % of Curcumin and 76.76±0.195 % of 
Cyclosporine are released and follows zero-order kinetics.  
The efficiency of drug-loaded pellets coated with Eudragit® S100 is 
evaluated on an acetic acid-induced ulcerative colitis rat model. It 
revealed the therapeutic efficacy of Eudragit® S100 coated 
bioadhesive pellets in alleviating the condition of colitis in the 
animal model which is reflected by weight gain along with the 
clinical, macroscopic, and microscopic parameters improvement of 
induced colitis when compared with free Curcumin and 
Cyclosporine [4]. Also, Curcumin and Cyclosporine combination at 
low doses was found to have a synergistic effect in the treatment of 
IBD in comparison with drugs at higher doses [11]. Hence Curcumin 
and Cyclosporine bioadhesive pellets with Eudragit® S100 coating 
may act as a tool for colon targeted delivery in the therapy and 
management of IBD [4]. 
 
Table 2: Various polymer and drug used in the approaches 
Approach Polymer  Drug  Reference 
Bioadhesive pellets Eudragit® S100, Hydroxypropylcellulose and 
Carbomer 940  
Curcumin, Cyclosporine [4] 
pH-sensitive polymeric coating Poly lactic-co-glycolic acid Budesonide [12] 
Calcium alginate–carboxymethyl cellulose beads Calcium alginate, Carboxymethyl cellulose beads  5-fluorouracil [13] 
Microcrystals with pH-sensitive multilayers Chitosan, Eudragit® S100 Dexamethasone [14] 
Disulfide cross-linked nanospheres Thiolated sodium alginate 5-amino salicylic acid [15] 
Dual pH and microbiota-triggered coating Eudragit® S, Starch Mesalamine [16] 
Edible ginger-derived nanoparticles - 6-gingernol, 6-shogaol [17] 
Dual Enzyme and pH-sensitive nanoparticles Eudragit® S, azo-polyurethane Coumarin-6 [18] 
Cyclodextrin inclusion complex Hydroxypropyl beta-cyclodextrin Fluticasone propionate [20] 
Microbiota sensitive coatings Nutriose: ethylcellulose 5-amino salicylic acid [23] 
Mucus penetrating nanosuspension enema Pluronic F127 coating Budesonide [24] 
Tablet in capsule formulation Hydroxypropyl methylcellulose, Eudragit E100 Mesalamine [31, 32] 
Nucleotide delivery vehicle Cationic konjac glucomannan Infliximab [35] 
Oral polymer Curcumin conjugate Polyethylene glycol Curcumin [36] 
Polymer based Oral Curcumin Eudragit® S100 Curcumin [37] 
Superoxide dismutase/catalase mimetic 
nanomedicine 
β-cyclodextrin Tempol [38] 
Polymeric nanocarriers Poly lactic-co-glycolic acid Cyclosporine A [39-43] 
 
Budesonide loaded nanoparticles with pH-sensitive coating 
The novel coated budesonide-loaded nanoparticles combine both the 
pH-sensitive and sustained drug release. Initial burst release or lack of 
pH sensitivity upon the oral delivery of conventional nanoparticles 
makes it limited for colon drug delivery. To overcome this 
nanoparticles with pH-sensitive polymeric coating are developed to 
minimize the release of the drug early in the upper part of the 
gastrointestinal tract. Oil in water (o/w) emulsion technique is used 
for the preparation of Budesonide and poly lactic-co-glycolic acid 
(PLGA) nanoparticles. Budesonide-loaded nanoparticles coated with 
pH-sensitive polymer are also prepared. Particle sizes of both the 
PLGA nanoparticles are found to be 200±10.1 nm and 240±14.7 nm 
respectively along with high encapsulation efficiency (85-90%) and a 
production yield of 90-94 %.  
In vitro dissolution studies showed that the coated PLGA 
nanoparticles reduced the initial burst release at acidic pH and 
released the drug only at neutral and alkaline pH in comparison with 
the uncoated PLGA nanoparticles, which proves that coated 
budesonide nanoparticles will minimize the adverse effects of the 
drug by facilitated localized treatment via oral administration. The 
therapeutic efficiency of both the coated nanoparticles and plain 
nanoparticles is evaluated in acute and chronic colitis mouse models 
along with the aqueous solution of the drug. The concentration of 
the drug remains equal in all three formulations (0.168 mg/kg). The 
results obtained shows that the coated PLGA nanoparticles pacified 
the induced colitis better than the Plain uncoated PLGA 
nanoparticles, which is already more effective than the treatment 
with the same dose of the free drug, which proved the application of 
budesonide loaded nanoparticles for targeted drug delivery to the 
intestinal mucosa, which can be further improved for oral 
administration by applying pH-dependent drug release 
characteristics [12]. 
Calcium alginate–Carboxymethyl cellulose beads 
Calcium alginate and carboxymethyl cellulose beads involve the mingled 
effects of pH sensitivity, colonic microbial degradation, and colon-
specific mucoadhesivity. Both Calcium alginate and carboxymethyl 
cellulose are biopolymers having a pH-dependent swelling behavior. 
Since both are anionic, this allows them to shrink in acidic pH and to 
swell upon exposure to neutral or basic pH. Along with the pH 
sensitivity, both the polymers also possess excellent mucoadhesive 
properties. The beads are prepared by the ionic gelation method. 5-
fluorouracil is loaded into the beads by swelling. The swelling study 
which is done at various pH such as 1.2, 6.8, and 7.4, have shown that the 
swelling is high in basic pH and low in acidic pH.  
Mucoadhesive test has shown that the beads have high mucoadhesivity 
for colon mucosa and minimum for stomach mucosa. In vitro colonic 
degradation carried out using colon microflora from human stool 
culture, affirmed that the beads are degradable wholly in phosphate 
buffer pH 7.4. In vitro dissolution study of the beads showed release of 
drug minimum in pH 1.2 and maximum release in pH 6.8. These data 
when combined along with the mucoadhesivity test have shown that the 
complete disintegration and drug release at colonic pH are possible. 5-
fluorouracil bioadhesive beads are further evaluated for their 
therapeutic potential using adenocarcinoma cell lines. 3-[4,5-
dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay is 
used for the evaluation of cell viability, which showed that after 48 h cell 
viability reduced undoubtedly after cells are exposed to the drug-loaded 
beads. The data obtained suggest these bioadhesive beads can be used as 
a promising colon targeting tool for the therapy of IBD [13]. 
Dexamethasone microcrystals with pH-sensitive multilayers 
Dexamethasone is used to treat mild to moderate forms of IBD. But long-
term use of such corticosteroids causes serious systemic side effects. 
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Moreover, corticosteroid dependence and side effects are observed 
mainly with their systemic administration. Reduction of unwanted 
effects and improved local bioavailability at targeted inflamed tissues 
can be achieved by the use of micro and nanoparticles employing 
concepts of pH-sensitive polymer coating and enzyme-dependent 
systems. However, they suffer from poor loading efficiency due to 
external phase crystallization during encapsulation. To overcome this, 
pH-sensitive layer-by-layer (LBL) coated dexamethasone microcrystals 
for colon targeted delivery are prepared.  
Dexamethasone microcrystals which are LBL coated using 
multilayers of chitosan oligosaccharide; alginate and pH-sensitive 
Eudragit® S100 polymer outermost coating for targeted colonic 
drug release and improving therapeutic efficacy. A pH-dependent 
drug release study is performed at different pH (1.2, 6.8, and 7.4) to 
closely mimic the pH of the gastrointestinal tract. For comparison 
the dexamethasone microcrystals without outer Eudragit® S100 
coating is also prepared. The results obtained reveal that the 
dexamethasone microcrystals containing only chitosan/alginate 
multilayers show burst release in pH 1.2 and 6.8, whereas the 
microcrystals containing Eudragit® S100 outer coating decreases 
the burst release of drug in pH 1.2 and 6.8 and shows more 
sustained release at pH 7.4. Drug release is further studied in the 
presence and absence of caecal contents to confirm sufficient drug 
release in the colon.  
As expected drug release rate of Eudragit® S100 coated 
dexamethasone microcrystals in contrast to the uncoated 
microcrystals remains unaffected in the presence of caecal contents. 
Dextran sulfate sodium-induced colitis model of mice is used to 
evaluate the in vivo anti-inflammatory activity of Eudragit® S100 
coated dexamethasone microcrystals. It showed that the Eudragit® 
S100 coated microcrystals effectively mitigated the symptoms of 
colitis. Therefore, the Eudragit® S100 coated dexamethasone 
microcrystals along with chitosan/alginate multilayer, efficiently 
reduces the pre-colonic loss of dexamethasone and increased colon 
dexamethasone availability and thus makes it a potential tool for the 
targeted delivery to the colon especially in IBD treatment [14]. 
Disulfide cross-linked nanospheres 
Even though many oral colon-specific drug delivery systems 
(OCSDDS) deliver drugs to the colon in enough concentration with 
no loss, the lack of selectivity to the inflamed lesions results in 
adverse effects. Therefore to increase the selectivity of the drug to 
the colonic lesions, nanospheres that are both pH-sensitive and 
reduction responsive are prepared for colon-specific drug delivery. 
Nanospheres are formulated by self-assembled amphiphilic 
thiolated sodium alginate (TSA) in deionized water which produces 
cross-linked disulfide bonds. Due to high concentrations of proteins 
inside the inflamed tissues with positive charges, it makes the 
negatively charged nanoparticles highly specific towards the 
inflamed tissues. Reduction cleavage of disulfide bonds in the colon 
causes triggered drug release from the carriers due to the standard 
reduction potential for the disulfide bond cleavage being lower than 
the reduction potential of the colon.  
The nanospheres are prepared by immobilization of 4-amino 
thiophenol on the sodium alginate backbone which is previously 
oxidized to sodium periodate, which forms self-assembled 
nanospheres which are crossly-linked in deionized water and are 
investigated for pH-sensitivity, reduction-response, and cell 
cytotoxicity, followed by the in vitro dissolution study. pH-sensitivity 
data showed that the particle diameter of the prepared nanospheres 
is minimum at acidic pH and maximum at pH 7.0. Reduction 
response studies conducted using pH 7.4 buffer containing 
glutathione of various concentrations (0, 10 µmol, and 10 mmol), the 
nanospheres remained stable in the solution without glutathione 
and with 10 µmol glutathione.  
In contrast, increased particle size and size distribution are noticed 
in a buffer solution containing millimolar glutathione. Cytotoxicity 
results showed no toxicity. In vitro, drug release studies performed 
using simulated gastric environment revealed that the cumulative 
amount of 5-amino salicylic acid released over 15 h from the 
microspheres is 25%, but in contrast 5-amino salicylic acid release is 
increased significantly, indicating the nanospheres disulfide bonds 
availability, which is cleaved by glutathione resulting in the 
increased 5-amino salicylic acid release, which can be used as a 
potential tool in the delivery of 5-amino salicylic acid to the inflamed 
colonic lesions in the therapy of IBD [15]. 
Dual pH and microbiota-triggered coating (Phloral™) 
Dosage forms for targeted delivery of drugs to the ileocolonic region 
are mostly based on enteric-coating technology. However accurate 
targeting of inflamed colonic lesions is not possible due to individual 
variabilities such as fluid pH and transit times which cause enteric 
coating failure. To overcome this Phloral™, which combines the 
principles of pH-triggered release (Eudragit® S; dissolving at pH 7) 
and microbiota triggered (resistant starch), has been developed for 
the foolproof approach to colonic drug targeting. It involves the use 
of resistant starch in a way that the pH-triggered release and outer 
enteric coating condition not gets affected. Starch granules are made 
more digestible for bacterial enzymes by heat treating it along with 
butanol to disrupt the crystalline structure. Swelling of starch across 
the upper gut is prevented by the outer Phloral™ enteric coating.  
The in vivo drug release studies performed using Kreb’s buffer pH 
7.4 by comparing with Eudragit® S coated tablets showed that the 
release of drug similar, indicating the absence of any effect on drug 
release by starch. Starch also acts as a secondary trigger, by 
accelerating the release of drugs by its degradation due to colonic 
bacteria; even though the pH of the colon in ulcerative colitis 
patients is low. This dual pH-enzymatic trigger coating provides an 
alternative way for colon-specific drug delivery despite the 
challenging conditions, such as reserved exposure to high pH in the 
distal intestine fluid and rapid transport across the colon, which will 
provide an exceptional delivery approach in treating IBD and other 
associated diseases [16]. 
Edible ginger-derived nanoparticles 
Existing treatment options for IBD include the use of anti-
inflammatory medications or immune suppressants. Despite these 
medications are effective their use remains narrow due to their 
indifferent immunological effects cause side effects such as nausea, 
allergic reactions, pancreatitis, and other life-threatening side 
effects. Also locally acting anti-inflammatory drugs with systemic 
absorption require high doses. Moreover sustained release dosage 
forms for colon-specific drug delivery are only effective in a 
particular subset of IBD patients. Anti-TNF-α agents are highly 
effective but their application is limited needed because they have to 
be systemically administered.  
Naturally, derived nanoparticles are both safe and profitable when 
compared with the restrictions of artificially derived nanoparticles 
such as toxic effects and limited manufacturing scale. 6-gingernol 
and 6-shogaol obtained from the ginger possess anti-oxidative, anti-
inflammatory, and anti-cancer activity. For treatment of IBD, the 
therapeutic efficiency of ginger-derived nanoparticles is examined. 
The prepared ginger nanoparticles are found stable in simulated 
gastric and intestinal conditions. Oral administration of the 
nanoparticles showed that they are retained in the colon which is of 
potential use in the treatment of IBD. Also, the ginger nanoparticles 
prevented the signs of inflammation at the histological level in drug-
induced colitis mice model.  
For analyzing potential toxicity colon-26 epithelial cell lines are used 
and as expected orally administered nanoparticles showed no 
effects in both intestinal epithelial cell proliferation and apoptosis. 
Orally administered ginger-derived nanoparticles target the colon 
efficiently and are taken up by epithelial cells and promoted mucosal 
healing in the colitis induced mice model. Also, it reduces colorectal 
tumors by inhibiting levels of cytokine, intestinal epithelial cell 
proliferation, and apoptosis. Thus ginger derived nanoparticles can 
be developed on large scale and represent an effective therapeutic 
strategy for therapy and management of IBD [17]. 
Dual enzyme and pH-sensitive nanoparticles 
In the treatment of IBD specific colonic drug delivery is desired for 
increasing the drug availability. Increased elimination due to IBD 
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associated high frequency diarrhea diminishes the ability of current 
dosage forms to deliver drugs to the inflamed colon. The majority of 
the commercialized colon drug delivery systems depend on pH 
changes in the digestive tract to deliver the drugs by using 
methacrylate copolymer (Eudragit® S 100). But sometimes the 
premature release of the drug from the above system causes systemic 
absorption of the drug, resulting in side effects. So to overcome these 
disadvantages, dual-sensitive nanoparticles were prepared by 
applying both pH-sensitive Eudragit® S and enzyme degradable azo-
polyurethane using Coumarin-6 as a model drug [18].  
Nanoparticles can accumulate in inflamed colon tissues and the 
combination helps in preventing immediate release in the stomach 
and facilitates the release only to the inflamed tissues by 
degradation of Eudragit® S-Azo-polyurethane nanoparticles 
prepared by O/W emulsion/solvent evaporation [18, 19]. The 
nanoparticles are then evaluated in buffers of various pH values (pH 
1.2, 4.0, and 7.4) for detecting pH-dependent morphological changes. 
At pH 1.2 and 4.0, the nanoparticles showed no signs of any 
morphological changes. Nanoparticles quickly dissolved, exhibited 
swelling, and maintained their morphology in pH 7.4 which implies 
their ability to reach the colon in particulate form. pH-dependent 
drug release study done in comparison with the plain Eudragit® S 
coated (without azo-polyurethane) nanoparticles showed that at pH 
1.2 and 4.0 the release of drug from the nanoparticles is less.  
At pH 7.4 the Eudragit® S coated nanoparticles with azo-
polyurethane, in contrast to the Eudragit® S coated showed no burst 
release and drug released more consistently. It shows that Eudragit® 
S coated nanoparticles with azo-polyurethane can retain the 
entrapped drug from the stomach and can release the drug in the 
colon efficiently which increases the drug availability desirable for the 
targeted colon delivery. The release study performed using rat 
gastrointestinal tract showed the ability of formulated nanoparticles 
achieves significantly high drug levels in the inflamed colon. These 
data suggest that Dual enzyme/pH-sensitive polymeric nanoparticles 
provide a suitable tool for colon-specific drug delivery for IBD [18]. 
Cyclodextrin inclusion complex 
Even though glucocorticoids form an important part of the therapy 
of IBD, they produce systemic side effects such as dyspepsia, moon-
face, hypertension, acne, insomnia, mood disturbances, and 
impaired glucose tolerance. Retention enemas and foam 
preparations are developed to avert these side effects. Fluticasone 
propionate is used topically for IBD, but it undergoes extensive first-
pass metabolism when given by oral route. Its low aqueous 
solubility does not permit mucosal transport of the drug, which 
leads to its poor oral absorption, which can be improved using a 
local drug transport to the inflamed tissues.  
Molecules of a certain size and shape along with the cyclodextrin 
form inclusion complexes. Because of water molecules release from 
cyclodextrin by the drug molecules and by attaining apolar-apolar 
association it improves the aqueous solubility of the poorly aqueous 
soluble drug. Hydroxypropyl beta-cyclodextrin, a derivative of 
cyclodextrin with improved aqueous solubility and decreased 
nephrotoxicity is selected is coated with Eudragit S 100. The 
intrinsic dissolution studies showed a practically 18 times rise in the 
dissolution of the drug upon complexation with Hydroxypropyl 
beta-cyclodextrin, which is due to the complexation of the drug 
converts crystalline into an amorphous form. In vitro dissolution 
studies showed zero release in 0.01 N HCl, which indicates the 
resistance of coated granules. In phosphate buffer pH 7.4, after 15 
min the release of the drug takes place with a burst release.  
Drug transport studies performed in vitro using rat colon show drug 
movement in inclusion complex across the membranes which are 
due to the increased drug solubility at the mucosal surface, upon 
formulation as an inclusion complex. These outcomes show that the 
above proposed inclusion complex can act as a colon targeted 
delivery system for the therapy of IBD [20]. 
Microbiota sensitive coatings 
Various advanced types of systems are proposed for colon-specific 
delivery, mainly pH-sensitive membranes, film coatings having time-
dependent permeability, pressure-sensitive film coatings, and 
preferentially bacterial enzymes degraded film coatings. Novel 
polymeric coatings are also developed to adapt to the 
pathophysiology of IBD patients. These film coating systems are 
enzymatically degraded in the affected colon. The 5-Amino salicylic 
acid (5-ASA) pellets with Nutriose: ethylcellulose coating [21, 22] 
has in vitro ability of retarding the release of drug in the gastric and 
small intestinal environment, and the release only happens upon 
exposure to media containing fresh fecal samples of patients. 
Macroscopic and histological evaluation is done by using rat colitis 
model and inflammatory markers measurement by Enzyme-linked 
immunosorbent assay (ELISA) and real-time polymerase chain 
reaction test (PCR) to determine in vivo efficacy of these coated 
pellets to treat inflammation. 
The active metabolite N-acetyl 5-ASA plasma concentration 
measured acts as an indicator to find the amount of drug released in 
the upper part of the gastrointestinal tract which is undesired. The 
severity of inflammation is significantly lowered by Nutriose: 
ethylcellulose pellets, much better in comparison with non-treated 
colitis group and Pentasa treated group as revealed by the 
macroscopic and histological evaluations which indicate the 
effectiveness of the developed colon targeting system. It also 
prevents drug release in the upper gastrointestinal tract and allows 
efficient targeting of the colon. The tissue sections showed that all 
the layers of the “vehicle-treated group” remained intact and in the 
“non-treated colitis group” exhibited severe signs of inflammation 
and also it remained the same in Pentasa treated groups. 
The measurement of pro-inflammatory markers in colon tissues 
showed that when treated with Nutriose: ethylcellulose pellets it is 
significantly low when compared with those treated with Pentasa or 
placebo pellets, by which in vivo efficacy of the proposed colon 
targeting system is also proved. Also increased 3-Hydroxy-3-
Methylglutaryl-CoA Synthase (HMG CS2) messenger ribonucleic acid 
(mRNA) and PPAR-γ (Peroxisome Proliferator-Activated Receptor-
γ) value indicates maximized gene and receptor activation and also 
increase in the concentration of 5-ASA at the targeted site. N-acetyl 
5-ASA plasma concentration is much lower upon treatment with the 
Nutriose: ethylcellulose pellets when compared with the rats 
receiving Pentasa pellets indicating that the proposed system 
effectively suppresses the release of 5-ASA in the upper part of the 
gastrointestinal tract since 5-ASA is actively converted into N-acetyl 
5-ASA in the stomach. All these data prove the efficiency of Nutriose: 
ethylcellulose microbiota-sensitive film coatings for colon targeting 
in the treatment of IBD [23]. 
Mucus penetrating nanosuspension enema 
For the treatment of active distal IBD locally administered 
micronized budesonide enema is one of the most common 
approaches. However, the micronized particles are limited for drug 
delivery to the inflamed tissues before clearance because they are 
large for penetrating the mucosal layer effectively. So for 
penetrating the mucus layer effectively and for increased drug 
delivery to the colon, it is formulated as nanosuspension with much 
inert Pluronic F127 coating for providing increased mucosal 
distribution and tissue penetration. The wet-milling method is used 
for preparing the budesonide nanosuspension coated with muco-
inert Pluronic F127 as well as a budesonide micro-suspension 
stabilized with Polyvinylpyrollidone which is used in the clinical 
application.  
The in vivo efficacy of the nanosuspension prepared is evaluated in 
trinitrobenzene sulfonic acid (TNBS) induced IBD. Treatment with 
budesonide nanosuspension results in a major reduction of 
macroscopic and microscopic symptoms of IBD compared to mice 
treated with the micro-suspension enema. Also, budesonide 
nanosuspension enema efficiently decreased the levels of 
inflammatory macrophages and Interleukin-β producing 
conventional dendritic 11b+cells in inflamed colon tissue in 
comparison to the micro-suspension enema treated mice. This 
indicates that the nanosuspension size and the muco-inert coating 
allowed increased delivery of the budesonide to the inflamed colon 
tissues and can be used as an alternative approach for targeting the 
colon in the therapy of IBD [24]. 
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Tablet in capsule formulation 
Mesalamine, the most commonly used drug for the treatment of IBD 
has to be administered frequently due to its large dose, which causes 
poor patient compliance. The Mesalamine enteric-coated pH-
dependent system is used for clinical application in the IBD treatment. 
However due to both the increased intestinal pH variability and acidic 
nature of the colon in IBD patients remains a challenge in achieving 
colonic drug targeting, by causing variability in vivo performance, site 
of disintegration, and also the appearance of commercially available 
enteric-coated tablets in the stools [25-29].  
Hence for reducing both the dose and administration frequency and 
for efficiently delivering drugs to the site of action, the tablet-in-
capsule system is developed consisting of enteric-coated 
hydroxypropyl methylcellulose (HPMC) capsules containing four 
units of core tablets each with 150 mg of Mesalamine, so that each 
capsule delivers 600 mg of Mesalamine which greatly reduces the 
frequency of administration and improves patient compliance. 
HPMC controls the Mesalamine release from the tablets [30], which 
is then further coated with Eudragit E100 polymer. Overall the 
release time from the capsules after it reaches the colon is found to 
be 7 h, 8 h, 9 h, and 10 h from 1st, 2nd, 3rd, and 4th
The in vitro drug release study showed that the enteric coating 
remained stable in the acidic pH and the release of the drug occurred 
only above pH 6.4. The in vivo study to evaluate the efficiency of the 
formulated capsules to release the Mesalamine is done by using the 
rabbit as an animal model. The roentgenographic study revealed that 
the capsules coated with Eudragit E 100 remain unscathed as far as 
the distal small intestine and the release from the capsule occurs only 
in the colon, which indicates that it can specifically deliver the drugs to 
the colon and will provide an alternative approach in colonic drug 
targeting in the treatment of IBD [32]. 
 unit respectively 
which is in par with the colon passage time of tablets (15-16 h) [31].  
Nucleotide delivery vehicle 
Tumor necrosis factor-α (TNF-α), a cytokine also has an important 
role in the pathogenesis of inflammation of Colon in IBD patients. In 
IBD patients increased levels of TNF-α causes the production of 
other pro-inflammatory cytokines. TNF-α blocking strategies have 
shown great potential for the treatment of IBD. A notable example is 
Infliximab which exhibits gratifying results in treating IBD in clinical 
trials [33]. But upon systemic administration, it causes 
immunodeficiency-related infections and generation of anti-drug-
antibodies. So they are needed to be limited at the specific site of 
inflammation even though they are effective.  
Hence orally-administered system for targeted delivery of anti-TNF-
α nucleotides to colonic macrophages has been developed. It 
consists of–i) cationic konjac glucomannan (cKGM), a soluble fiber 
extracted from Amorphophallus konjac, ii) phytagel, and iii) an 
antisense molecule (ASO) against TNF-α. cKGM has many functions, 
it forms nano-complex core by conjugation with negatively charged 
ASO, second, it has mannose moieties which are recognized by 
mannose receptors in the macrophages, resulting interaction causes 
the phagocytosis, also cKGM shows increased water absorption and 
immediately swells [34]. Phytagel in contrast swells poorly and this 
contrast swelling property results in collapse of the system in the 
colon.  
The prepared formulation showed less toxicity when checked for 
cytotoxicity. In vitro transfection study done to observe the 
transfection efficiency of cKGM and ASO in macrophages and colonic 
epithelial cells, showed that cKGM greatly increased the transfection 
of ASO, which shows that cKGM may produce antisense molecule 
transport partly through mannose mediated endocytosis. Tissue 
distribution and cellular localization studies done in mice showed 
the enhanced aggregation of antisense molecules in the colon. 
Immunofluorescence staining study showed that TNF-α level in the 
mucosa are greatly reduced. Marked histological development is 
apparent when treated with antisense molecule containing cKGM in 
colitis-induced mice. These results suggest the potential of this 
cKGM containing system as an advantageous route allowing the 
highly effective colonic nucleic acid drug delivery which will be 
useful in the colonic drug targeting for the treatment of IBD [35]. 
Oral polymer curcumin conjugate 
Various natural products have been investigated for their 
application in treating IBD, to overcome the soaring price, adverse 
effects, and nonspecific effects of the synthetic drugs after 
administration. Curcumin obtained from rhizomes of Curcuma longa, 
is currently having high consideration for treating IBD due to its 
lowering cost, steady sources, and also for its excellent anti-
inflammatory activity, which is reported in many clinical trials. But 
its clinical application for the treatment of IBD remains a challenge 
due to its meagre aqueous solubility and bioavailability.  
So an effective delivery system involving nanoparticles has been 
developed for improved colonic tissue targeting, better therapeutic 
efficacy, and reduced unwanted effects. Nano-sized delivery systems 
are employed because of their advantageous aggregation in the 
inflamed colonic tissues (especially size of ~100 nm). It is prepared 
by condensation polymerization reaction which involves the 
formation of disulfide bonds between hydrophobic Curcumin and 
hydrophilic polyethylene glycol. The release of Curcumin is by the 
reduction of the drug-polymer conjugate by the colonic bacteria. 
This nano size and neutral charged surface results in precise colonic 
tissue deposition, along with enhanced partition coefficient which 
facilitates transmembrane transport and increased oral availability.  
The polymer Curcumin conjugate is then evaluated both in vivo and 
in vitro. In vitro release studies showed release of drug less in gastric 
fluid and high release in medium with rat caecal contents. In vivo 
studies for evaluating therapeutic efficiency using murine IBD, 
model showed that the polymer-drug conjugate significantly 
alleviates the induced colitis in mice which is illustrated by 
multifaceted regulation and mediation of IBD-related indicators. 
Results from both the in vivo and in vitro studies showed that 
polymer-drug conjugate possesses suitable physicochemical 
properties to overcome the gastric environment for providing 
preferential accumulation in the inflamed intestinal tissues, which 
gives us an alternative approach for the treatment of IBD [36]. 
Polymer based oral curcumin (Ora-Curcumin-S) 
Current treatment for IBD focuses only on the established disease 
but cannot thwart or restrict its advancement. To specifically target 
the luminal side of the colon for restricting and/or managing IBD, 
polymer based Ora-Curcumin-S is investigated. It is developed by 
molecular expression of Curcumin and Eudragit® S100 by co-
precipitation method in which Curcumin becomes non-crystalline 
because of non-covalent polymeric interactions. It is different from 
solid dispersions, because in polymer-drug complex despite 
dissolving in aqueous buffers the interactions are maintained. Ora-
Curcumin-S has 1000 times enhanced aqueous solubility relative to 
Curcumin and soluble only above pH 6.8 (pH-dependent). 90% of 
Ora-Curcumin-S remained stable in phosphate buffer pH 7.4 as well 
as in intestinal fluid after 24 h as opposed to 10-20% unformulated 
Curcumin.  
The formulated Ora-Curcumin-S is a Toll-like receptor-4 (TLR-4) 
antagonist as it inhibits Monophosphoryl lipid-A and E-coli 
influenced inflammatory effects in dendritic cells and cells over 
expressing TLR-4. Preliminary pharmacokinetic studies confirmed 
colon targeted delivery of soluble Curcumin to the colon with no 
systemic circulation exposure. Also, Ora-Curcumin-S remarkably 
prevents colitis and linked injury in a mouse model which is 
assessed by diverse preclinical parameters such as colonoscopy 
pictures, body weight, spleen weight, colon length and edema, pro-
inflammatory signaling, and independent pathological scoring. This 
study showed that Ora-Curcumin-S provides a locally targeted 
pathway for IBD treatment, which reduces both inflammation and 
vulnerability to colitis associated colorectal cancer [37]. 
Superoxide dismutase/catalase mimetic nanomedicine 
Oxidative stress which is due to the over a generation of reactive 
oxygen species (ROS) causes IBD initiation and progression. A 
superoxide dismutase/catalase mimetic nanomedicine with 
hydrogen peroxide-eliminating nanomatrix and free radical 
scavenger Tempol is developed. Oxidation-responsive β-
cyclodextrin material is added to the above to form Tempol loaded 
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oxidation-responsive β-cyclodextrin nanoparticle (Tpl/OxbCD). On-
demand release of Tempol from molecules of Tpl/OxbCD is 
triggered by hydrolysis of oxidation-responsive β-cyclodextrin 
material. The Tpl/OxbCD efficiently accumulates in the inflamed 
mice colon, whereby it reduces nonspecific distribution after oral 
delivery. Oral administration of the Tpl/OxbCD lessened colitis-
related manifestations and abolished proinflammatory mediators in 
colitis induced mice models upon oral administration with superior 
efficacy over free tempol. The Tpl/OxbCD can be applied as an 
effective nanomedicine for the treatment of IBD and other related 
conditions [38]. 
Polymeric nanocarriers 
For ideal treatment in IBD, a maximum concentration of drug in the 
affected tissue is needed, which is difficult when the target tissue 
acts as an absorptive tissue, where the drug is instantly absorbed 
from the intestinal lumen into the systemic circulation. 
Corticosteroids used for inducing remission and to prevent relapses 
cannot be given over large periods of time because of their systemic 
side effects [39]. This can be overcome by specific targeting of drugs 
to the affected tissues by formulating into nanoparticles.  
Cyclosporine A an immunosuppressive drug causes serious side 
effects [40-42] that are minimized by formulating into nanoparticles, 
which are being processed by nanoprecipitation method, and for 
microparticles, nanospray drying is used. PLGA is the polymer 
involved which is biodegradable and applied in various 
pharmaceutical products. The therapeutic efficacy study is carried 
out using a dextran sodium sulfate (DSS) induced colitis model in 
comparison with a marketed oral formulation and also with drug-
free Nanoparticle and Microparticles. The histopathological analysis 
demonstrated that the cyclosporine nanoparticles provided better 
remedial and shielding effect on mice mucosa than microparticles 
and commercially available formulation, which can be seen by 
mitigated manifestations related to colitis, and suppressed pro-
inflammatory mediators in colitis induced mice models.  
There is a significant improvement in the shielding effect of 
cyclosporine A on the intestinal animal mucosa when compared 
with other formulations. Plasma level quantifications showed that 
the drug is localized in the target area and not absorbed 
systemically. These results combinedly reveal the true potential of 
polymeric nanoparticles as a productive proposition for colonic drug 
targeting in IBD therapy and other associated conditions [43]. 
Nanostructured lipid carriers 
Vitamin D3 (calcitriol) or 1,25-dihydroxycholecalciferol is found 
deficient in serum of IBD patients, mainly with Crohn's disease, 
which is doubted to play an important role in IBD pathogenesis and 
development. In vitro investigations using IBD animal models 
disclosed that vitamin D3 suppressed IBD development by 1) innate 
and acquired immunity suppression by direct and regulation of 
cytokine-mediated immune cells 2) mucosal barrier healing by 
impacting intestinal epithelium 3) maintaining gut microbiome 
balance by initiating antimicrobial peptides secretion from 
macrophages and paneth cells, which makes it beneficial in 
comparison to the current drugs. However clinical trials revealed 
that large doses of vitamin D3 or its prodrug are required to improve 
the symptoms of Crohn’s disease and to reduce relapse rate. But a 
high dose of vitamin D3
Hence efficient transit is developed by using nanostructured lipid 
carriers so that the dose administered gets reduced. The principle 
behind these carriers is that they remain strong in gastric fluid, but 
steadily gets degenerated by intestinal enzyme lipase that is present 
in the intestinal fluids, which simultaneously intensifies the vitamin 
D
 produces hypercalcemia and other 
associated side effects [44].  
3 intestinal absorption. Since vitamin D3 is not stable at high 
temperatures and the use of ultra-sonication is not desired due to 
the generation of radical species, nanostructured lipid carriers are 
prepared by the O/W emulsion method. In vitro studies revealed 
that the nanostructured lipid carriers containing vitamin D3 are 
actively up taken by the macrophages in the inflamed lesions but 
showed no toxicity. Also, the nanostructured lipid carriers showed 
an anti-inflammatory effect by activating the nuclear factor kappa 
light chain enhancer of the activated B cells (NF-kβ) pathway. Upon 
comparison with saline dispersion, the nanostructured lipid carriers 
significantly increased the colonic concentrations of vitamin D3 and 
also maintained the level for 12 h which shows the sustained release 
of vitamin D3
CONCLUSION 
 by the nanostructured lipid carriers. The 
nanostructured lipid carriers also undoubtedly repressed the 
disease development in the DSS-induced colitis model. These results 
show that the nanostructured lipid carriers offer an alternative 
pathway for the treatment of IBD by acting through a different 
mechanism from the currently available drugs and its potential in 
the therapy of IBD [45]. 
The above discussed approaches differ from the conventional 
approach used for the treatment of IBD, either by offering a new 
drug delivery system for already available drugs or by the use of a 
natural substitute for efficient colonic drug targeting. The suitability 
of the above mentioned systems for clinical treatment remains a 
huge doubt. Even though the above mentioned studies revealed the 
potential of these approaches as a substitute for the IBD treatment, 
it is undeniable that the targeting effectiveness of these approaches 
concerned still requires to be improved. Further developmental 
studies are needed to be carried out for the clinical application of 
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